RELEVANCE. A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOM. GELA /Grupos cooperativos europeos.

Investigador Principal	Dr. Armando López Guillermo ([email protected])
Estado del Protocolo	Cerrado
Fecha prevista de inicio
ULTIMO NEWSLETTER	DESCARGAR PROTOCOLO